We thank Dr. Davies for the interest in our work and for his comments.
About the specific comment on the title of the paper, it is difficult to assess breakthrough pain (BTP), especially in patients with incident pain who avoid certain movements that might trigger pain. The criteria to include patient-controlled analgesia (PCA) in the present work were "if a certain patient presented with severe BTP requiring at least five doses or rescue systemic opioid analgesia or previous attempt to improve pain control." In the next paragraph, we used the definition described by Haugen et al. [1] , that can certainly be misunderstood in the present reading. The questions pointed by Dr. Davies concerning the review article by Haugen et al. [1] are correct, "it's certainly questionable to characterize and treat BTP when baseline pain is not controlled." We agree with this.
However, we described the use of PCA in patients with and without BTP. All patients described in this work had been submitted to the standard therapy provided by the oncologist; the most difficult to treat had "incident pain" or "movementrelated pain," but were pain-free most of the time. Some patients, that we diagnosed as suffering from BTP, were hospitalized and had to leave their rooms several times a day, in order to be submitted to procedures, and suffered pain when moved from one place to the other. That type of pain is in accordance to the definition of BTP described by Davies [2] .
As to the observation about other therapeutics options, in our institution, PCA is a safer, timely, and useful system than traditional methods to treat patients with severe BTP but is certainly not the only one.
In conclusion, we are thankful for the comments and for pointing out further research possibilities.
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